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Abstract
Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of cancers,
making PRMTs potential therapeutic targets. But it remains not well understood how PRMTs impact specific oncogenic
pathways. We previously identified PRMTs as important regulators of cell growth in neuroblastoma, a deadly
childhood tumor of the sympathetic nervous system. Here, we demonstrate a critical role for PRMT1 in neuroblastoma
cell survival. PRMT1 depletion decreased the ability of murine neuroblastoma sphere cells to grow and form spheres,
and suppressed proliferation and induced apoptosis of human neuroblastoma cells. Mechanistic studies reveal the
prosurvival factor, activating transcription factor 5 (ATF5) as a downstream effector of PRMT1-mediated survival
signaling. Furthermore, a diamidine class of PRMT1 inhibitors exhibited anti-neuroblastoma efficacy both in vitro and
in vivo. Importantly, overexpression of ATF5 rescued cell apoptosis triggered by PRMT1 inhibition genetically or
pharmacologically. Taken together, our findings shed new insights into PRMT1 signaling pathway, and provide
evidence for PRMT1 as an actionable therapeutic target in neuroblastoma.
Introduction
Overexpression of protein arginine methyltransferases
(PRMTs) has been well documented in various cancers
and is often correlated with poor prognosis1. PRMT1 and
PRMT5 are primary type I and II enzymes that are
responsible for most asymmetrical di-methylarginine
(aDMA) and symmetrical di-methylarginine (sDMA)
marks, respectively1. Emerging evidence has linked inhi-
bition of PRMTs to perturbation of multiple aspects of
cancer cell behavior, including transformation, prolifera-
tion, invasiveness, and survival2. Thus, PRMTs may
represent attractive cancer targets for small molecule
inhibition. But it remains not well understood how
PRMTs impact specific oncogenic pathways.
Our previous work demonstrated critical roles of
PRMT1 and PRMT5 for neuroblastoma cell growth in
part through arginine methylation of MYCN and sub-
sequent enhancement of its stability3,4. Amplification of
MYCN is found in about 25% of neuroblastoma, the most
common extracranial solid tumor of childhood, and cor-
relates with poor outcome5. MYCN-amplified tumors
exhibited high levels of PRMT1 and PRMT5; knockdown
of either PRMT1 or PRMT5 led to downregulation of
MYCN and suppression of cell growth, suggesting a
dependence of MYCN-amplified neuroblastoma on
PRMTs3,4. We and others further found a significant
correlation between high levels of PRMT1 and unfavor-
able patient outcome irrespective of MYCN amplification,
thus implying potential MYCN-independent mechanisms
for PRMT1 in neuroblastoma3,6.
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Here, we reveal a novel role of PRMT1 in promoting
neuroblastoma cell survival. We identified activating
transcription factor 5 (ATF5) as a key downstream
effector that mediates prosurvival function of PRMT1. We
further showed that diamidine-related PRMT1 inhibitors
displayed anti-neuroblastoma effects both in cell culture
and in tumor-bearing mice. Our results suggest that
PRMT1 may represent an attractive, druggable target for
neuroblastoma.
Results
PRMT1 is crucial for the maintenance of murine
neuroblastoma sphere cells
Our recent studies showed that mouse neuroblastoma
sphere-forming cells derived from neuroblastoma tumors
in Th-MYCN mice possess self-renewal, differentiation,
and tumorigenic potential7. We first confirmed that these
cells exhibited self-renewal capacity both in vitro and
in vivo (Supplementary Figure S1). We found that sphere
cells displayed higher levels of PRMT1 and MYCN, as
well as Phox2B, a specific biomarker of neuroblast pro-
genitor cells, compared to those in primary tumors, as
shown in both Western blot and immunostaining (Fig. 1a,
b). Our previous observations that PRMT1 was essential
for human neuroblastoma cell growth3 prompted us to
examine whether PRMT1 is required for the growth of
sphere cells. By using a previously verified
shPRMT1 sequence8, we were able to efficiently knock-
down PRMT1 in sphere cells, as shown in Western blot
(Fig. 1c). PRMT1 depletion markedly inhibited sphere cell
growth (Fig. 1d) and impaired their self-renewal capacity
(Fig. 1e). These data suggest that PRMT1 plays an
essential role in the maintenance of neuroblastoma
sphere-forming cells.
PRMT1 is essential for the proliferation and survival of
human neuroblastoma cells
To overcome cell growth arrest upon constitutive
PRMT1 knockdown as shown in sphere cells (Fig. 1) and
in human neuroblastoma cell lines described in our prior
work3, we established inducible PRMT1 depletion by
using previously validated shPRMT1 sequences3. Upon
the addition of doxycycline (Dox), PRMT1 was efficiently
depleted in MYCN-amplified human neuroblastoma cell
line Kelly, as demonstrated by western blot in two inde-
pendent shPRMT1 constructs-transduced cells (Fig. 2a).
PRMT1 knockdown dramatically suppressed Kelly cell
proliferation in both shPRMT1 lines (Fig. 2b), which is
consistent with our previous observations in LAN-5 cells
upon transient PRMT1 depletion3. Importantly, the cri-
tical role of PRMT1 was further confirmed in another
MYCN-amplified human neuroblastoma cell line [SK-N-
BE(2)C] using two independent shPRMT1-1 clones D6
and C9 (Fig. 2c, d). We next asked whether PRMT1 plays
a similar role in MYCN-non-amplified cells. We then
depleted PRMT1 in two independent MYCN-non-ampli-
fied neuroblastoma cell lines SK-N-AS and SH-EP1, and
observed similar suppression of cell proliferation in both
cell lines (Supplementary Figure S2A-D). Taken together,
these findings indicate that PRMT1 may play a general
Fig. 1 PRMT1 is required for the maintenance of murine neuroblastoma sphere cells. a Western blot of Th-MYCN primary tumors and murine
neuroblastoma sphere cells (2 and 34 days in culture). b IHC staining in murine neuroblastoma sphere cells. c Western blot of murine neuroblastoma
sphere cells transduced with shScramble or shPRMT1-1 lentiviruses. d Sphere-growth assay of murine neuroblastoma sphere cells. Data are mean ±
SD (n= 3) relative to day 1. e Sphere-forming assay of murine neuroblastoma sphere cells. Data are mean ± SD (n= 3) relative to scramble. **P < 0.01.
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role for neuroblastoma cell proliferation. However, we
cannot rule out the possibility that MYCN may contribute
to some phenotypes after PRMT1 silencing in MYCN-
amplified cells.
To understand how PRMT1 regulates neuroblastoma
cell behavior, we first evaluated effects of PRMT1 deple-
tion on cell cycle progression. Dox-induced PRMT1
knockdown did not appear to significantly affect cell cycle
progression (Supplementary Figure S2E), suggesting that
the reduction of cell growth upon PRMT1 silencing might
be due to an increase of cell death. To test this idea, we
performed two independent experiments to investigate
the effect of PRMT1 attenuation on the incidence of cell
apoptosis. First, PRMT1 knockdown induced apoptosis in
both Kelly and SK-N-BE(2)C cells, as evidenced by
increased caspase-3/7 activity (Fig. 2e, f). Second, Western
blot further confirmed the cleavage of PARP in PRMT1-
depleted Kelly and SK-N-BE(2)C cells (Fig. 2g, h). These
observations demonstrate that PRMT1 is a crucial factor
for neuroblastoma cell survival.
To verify the specificity of shRNA-mediated knock-
down, we reintroduced into SK-N-BE(2)C shPRMT1-D6
cells an empty vector (pOZ) or Flag-PRMT1 (pOZ-
PRMT1) that carries silent mutations to avoid knockdown
by the shRNA construct8. We first performed western
blot of these cell lines and verified the expression of
ectopic Flag-PRMT1 (Fig. 2i). As observed in the cell
proliferation (Fig. 2j) and caspase-3/7 (Fig. 2k) assays,
introduction of Flag-PRMT1 reversed inhibition of cell
proliferation, as well as induction of caspase-3/7 activity
upon PRMT1 depletion, thus excluding possible off-target
effects of shRNA knockdown.
Fig. 2 PRMT1 is essential for the proliferation and survival of human neuroblastoma cells. a Western blot of Kelly cells stably expressing Dox-
inducible shRNA targeting PRMT1 or scramble. shPRMT1-1 and shPRMT1-2 are two independent shPRMT1 constructs. b PRMT1 depletion suppressed
Kelly cell proliferation. Data are mean ± SD (n= 3) relative to scramble without Dox (100%). cWestern blot of SK-N-BE(2)C cells stably expressing Dox-
inducible shRNA targeting PRMT1-1 or scramble. D6 and C9 are two independent shPRMT1-1 clones. d PRMT1 depletion suppressed SK-N-BE(2)C cell
proliferation. Data are mean ± SD (n= 3) relative to scramble without Dox (100%). Caspase-3/7 activity assay in Kelly shPRMT1-1 cells (e) and SK-N-BE
(2)C shPRMT1-D6 cells (f) with or without Dox. Data are mean ± SD (n= 3) relative to cells without Dox. Western blot of Kelly shPRMT1-1 cells (g) and
SK-N-BE(2)C shPRMT1-D6 cells (h). i Western blot of SK-N-BE(2)C shPRMT1-D6 cells transduced with pOZ vector or pOZ-PRMT1. j Cell proliferation
assay of SK-N-BE(2)C shPRMT1-D6 cells transduced with pOZ vector or pOZ-PRMT1 with or without Dox. Data are mean ± SD (n= 3) relative to day 1.
k Caspase-3/7 activity assay of SK-N-BE(2)C shPRMT1-D6 cells transduced with pOZ vector or pOZ-PRMT1 with or without Dox. Data are mean ± SD
(n= 3) relative to pOZ without Dox. **P < 0.01.
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PRMT1 promotes neuroblastoma cell survival through
ATF5
To define the molecular mechanisms by which PRMT1
promotes neuroblastoma cell survival, we performed
RNA-seq analysis in PRMT1-depleted SK-N-BE(2)C cells
to identify potential target genes and downstream sig-
naling pathways. Gene ontology (GO) enrichment and
KEGG pathway analyses of differentially expressed genes
identified apoptosis and regulation of MAPK kinase
activity among the most significantly regulated pathways
(Fig. 3a, b). Here, we elected to focus on the prosurvival
gene, activating transcription factor 5 (ATF5), one of the
most highly downregulated genes in PRMT1-depleted
cells. To our knowledge, there have been no previous
reports on the oncogenic role of the PRMT1-ATF5 axis in
neuroblastoma.
ATF5 belongs to the basic leucine zipper family of
transcription factors and plays a critical role in modulat-
ing cellular differentiation and tissue development in
various compartments9. It has been hypothesized that
dysregulation of ATF5 may serve as a survival factor in
cancer development, notably gliomagenesis9. There have
been no published reports to date linking ATF5 to neu-
roblastoma tumorigenesis, even though the potential role
Fig. 3 PRMT1 promotes neuroblastoma cell survival through ATF5. a, b Gene ontology analyses of differentially expressed genes in SK-N-BE(2)C
cells after PRMT1 depletion. c qRT-PCR (top) and Western blot (bottom) of SK-N-BE(2)C shPRMT1-D6 with or without Dox. Data are mean ± SD (n= 3)
relative to without Dox. d Western blot of SK-N-BE(2)C shPRMT1-D6 cells transduced with pOZ vector or pOZ-ATF5. e Cell proliferation assay of SK-N-
BE(2)C shPRMT1-D6 cells transduced with pOZ vector or pOZ-ATF5 with or without Dox. Data are mean ± SD (n= 3) relative to day 1. f Caspase-3/7
activity assay of SK-N-BE(2)C shPRMT1-D6 cells transduced with pOZ vector or pOZ-ATF5 with or without Dox. Data are mean ± SD (n= 3) relative to
pOZ without Dox. g qRT-PCR of cells transfected with ON-TARGETplus human siPRMT1 pool or ON-TARGETplus Non-targeting pool. HPRT1 was used
as an internal control. Data are mean ± SD (n= 3) relative to cells transfected with Non-targeting pool. h UCSC genome browser tracks of the ATF5
gene locus showing PRMT1 binding with two different antibodies. i ChIP analysis of PRMT1 at ATF5 and CITED2 gene promoters in SK-N-BE(2)C cells.
j ChIP analysis of H4R3me2a at ATF5 and CITED2 gene promoters in SK-N-BE(2)C shPRMT1-D6 cells with or without Dox. Data are mean ± SD (n= 3).
**P < 0.01.
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of ATF5 in neuroblastoma cell survival has been impli-
cated in recent conference abstracts. Yamashiro’s group
identified ATF5 as a potential synthetic lethal gene to
MYCN-amplified neuroblastoma10. Their initial studies
demonstrate that ATF5 is highly expressed in MYCN-
amplified tumors, and that silencing of ATF5 inhibits cell
proliferation and induces cell apoptosis10,11. They further
show that an ATF5-targeting peptide has profound
in vitro and in vivo cytotoxic and apoptotic effects on
neuroblastoma11.
We report here, to our knowledge, PRMT1 as a novel
regulator of ATF5 in neuroblastoma. We first performed
RT-qPCR analysis to verify the downregulation of ATF5
mRNA expression in PRMT1-depleted cells (Fig. 3c).
Notably, PRMT1 ablation reduced ATF5 expression at
the protein level as well (Fig. 3c), confirming that PRMT1
is required for ATF5 expression and might be an
upstream activator of ATF5 expression. Furthermore, we
also observed a marked decrease of ATF5 mRNA in
another MYCN-amplified cell line Kelly after
PRMT1 silencing (Fig. 3g). To test the functional role of
ATF5, we overexpressed Flag-tagged ATF5 in SK-N-BE
(2)C shPRMT1-D6 cells and verified the expression of
ectopic ATF5 (Fig. 3d). Next, we performed two inde-
pendent assays to examine the functional requirement of
ATF5 in PRMT1-mediated survival pathway. First, we
monitored cell proliferation by using Alamar blue assay
and found that ectopic expression of ATF5 rescued the
inhibition of cell proliferation upon PRMT1 silencing
(Fig. 3e). Second, we evaluated cell apoptosis by using
caspase-3/7 activity assay and observed that Dox-
mediated PRMT knockdown induced cell apoptosis in
pOZ vector-transduced cells, but not in cells ectopically
expressing ATF5 (Fig. 3f). These results indicate that
ATF5 is a downstream functional effector of PRMT1-
mediated survival pathway.
Given that our prior study implicated MYCN as an
important target of PRMT13, we are aware of the poten-
tial contribution of MYCN to the gene expression changes
after PRMT1 silencing in MYCN-amplified cells. In
addition, ATF5 was recently identified as a potential
synthetic lethal gene to MYCN10, raising the possibility
that ATF5 may be directly or indirectly regulated by
MYCN. To test whether PRMT1 regulates ATF5
expression independent of MYCN, we measured ATF5
expression in three MYCN-non-amplified cell lines after
PRMT1 silencing, two of which, SK-N-AS and SH-SY5Y
displayed a marked decrease of ATF5 expression upon
PRMT1 depletion (Fig. 3g). Importantly, PRMT1 silencing
also suppressed cell proliferation in these cell lines
(Supplementary Figure S2A-D). It is possible that MYCN
may contribute to the regulation of ATF5 in MYCN-
amplified cells. Nevertheless, these results support the
notion that the PRMT1-ATF5 axis plays a critical role in
neuroblastoma cell growth and survival, regardless of
MYCN amplification status.
We next set out to evaluate the mechanisms by which
PRMT1 regulates ATF5 expression. We have previously
demonstrated a cross-talk between H4R3me2a mark
deposited by PRMT1 and subsequent histone acetylation,
as well as the recruitment of general transcription
machinery8,12. These findings lead us to hypothesize that
PRMT1 may activate ATF5 transcription through mod-
ulating H4R3me2a mark. First, to assess whether PRMT1
binds to the ATF5 locus, we retrieved our recent ChIP-
seq results in human keratinocytes expressing HA-
PRMT113. By using two different antibodies, we
observed PRMT1 peaks that were enriched at the ATF5
gene locus (Fig. 3h). Importantly, ChIP-qPCR demon-
strated enrichment of PRMT1 at ATF5 gene promoter in
SK-N-BE(2)C cells, but not at CITED2 gene promoter
whose mRNA level did not change in PRMT1-depleted
cells (Fig. 3i). Finally, ChIP further demonstrated that
silencing of PRMT1 dramatically reduced H4R3me2a
enrichment at ATF5 gene promoter, but not at CITED2
gene promoter where H4R3me2a was not enriched
(Fig. 3j). Taken together, these data indicate that PRMT1
promotes cell survival through modulating H4R3me2a
mark at ATF5 gene and thus activating its transcription
and prosurvival activity. It is important to note that
additional experiments are needed to test whether
PRMT1 directly regulates ATF5 transcription. For
instance, the unspliced form of ATF5 mRNA should be
measured upon PRMT1 silencing. Furthermore, a luci-
ferase reporter mini-gene containing or not containing
ATF5 promoter regions bound by PRMT1 should be used
in stably transfected MYCN-non-amplified cells to
examine the reporter activity and H4R3me2a enrichment
in the presence or absence of PRMT1.
Diamidine compounds inhibit neuroblastoma cell growth
To date, pharmacological inhibition of PRMT1 activity in
tumors has not been fully explored largely due to limited
specificity and selectivity of most currently available inhibi-
tors14. Focused library screenings by us and others have
identified low micromolar PRMT1 inhibitors, including the
diamidine compound furamidine and its analogs15–18 (Fig.
4a). We have studied the structure-activity relationships of
diamidine-related compounds by assaying their ability to
inhibit neuroblastoma cell growth19. First, we found that
treatment with two of diamidine compounds, furamidine and
decamidine led to a concentration-dependent reduction of
cell viability in murine neuroblastoma sphere cells with
decamdine exhibiting much higher potency than furamidine
(Fig. 4b). TC-E5003, a selective PRMT1 inhibitor that does
not belong to the diamidine family20 also displayed sup-
pression of sphere cell viability similar to decamidine (Fig.
4b), thus supporting that PRMT1 activity plays an essential
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role in neuroblastoma sphere cells. Importantly, EPZ020411,
a PRMT6-selective inhibitor21, did not affect sphere cell
viability at the highest concentration tested (Fig. 4b). Next,
we expanded our studies to a wide panel of human neuro-
blastoma cell lines, including MYCN-amplified [SKN-BE(2)-
C, LAN-5, and KELLY] and MYCN-non-amplified (SH-
SY5Y, SK-N-AS, and SH-EP1) cell lines (Fig. 3c–g). The
cytotoxicity of diamidine compounds largely correlated with
their in vitro PRMT1 inhibitory effects as determined by
biochemical assays with synthetic PRMT1 substrates15. The
inhibitory effect on neuroblastoma cell viability follows the
rank order decamidine >TCE5003 > hexamidine > pentami-
dine > furamidine. Interestingly, these compounds exhibited
similar potency in MYCN-amplified versus non-amplified
neuroblastoma cell lines, which is consistent with a similar
reduction of cell proliferation upon PRMT1 silencing
regardless ofMYCN amplification (Fig. 2 and Supplementary
Figure S2). In addition, we noticed that many, if not all,
diamidine compounds showed much higher potency in
sphere cells than in neuroblastoma cell lines. This differential
potency could be simply due to different species between
mouse neuroblastoma-derived sphere cells and human
neuroblastoma cell lines. Another possible scenario is that a
small cancer stem-like subpopulation in sphere cells may
present unique vulnerability to PRMT1 inhibition. To test
this idea, further studies are needed to compare the potency
of PRMT1 inhibitors in isolated neuroblastoma cancer stem
cell fraction based on certain surface markers (i.e., CD133
and FZD6) to that in neuroblastoma cell lines from the same
species. Whether and how PRMT1 plays differential roles for
survival of neuroblastoma spheres versus cell lines awaits
further investigation. Nevertheless, our results are consistent
with the notion that, despite several known activities of
diamidine-related compounds14, their anti-proliferative
activity in neuroblastoma cells relates, at least in part, to
their inhibition against PRMT1.
Pharmacological inhibition of PRMT1 induces
neuroblastoma cell apoptosis
To determine molecular mechanisms of cell growth
inhibition by diamidine compounds, we chose the most
potent diamidine compound, decamidine and first asked
whether decamidine induces apoptosis in cell culture.
Indeed, in two independent human neuroblastoma cell
lines SK-N-BE(2)C and Kelly, we observed an increase of
caspase-3/7 activity, as well as cleaved PARP upon
treatment with low micromolar concentrations of dec-
amidine (Fig. 5a–d). Notably, western blot indicated a
dose-dependent decrease of ATF5 protein level in both
cell lines (Fig. 5b, d). These data suggest that pharma-
cological inhibition of PRMT1 activity phenocopies
genetic ablation of PRMT1 toward downregulation of
prosurvival signaling and induction of cell apoptosis. To
gain direct insight into cellular mechanisms of dec-
amidine, we treated SK-N-BE(2)C cells with 4 μM dec-
amidine for 24 h and examined transcriptional changes
using RNA-seq. Among the top 10 significantly regu-
lated pathways, PI3K-Akt signaling pathway, ECM-
Fig. 4 Diamidine compounds reduce cell growth in murine neuroblastoma sphere cells and human neuroblastoma cell lines. a A list of
diamidine-related PRMT1 inhibitors. IC50 values were previously determined by in vitro biochemical assays16. b Cell viability of murine neuroblastoma
sphere cells treated with indicated compounds for 3 days. Cell viability was determined by using Alamar blue assay and normalized to DMSO-treated
cells (100%). c–g Cell viability of human neuroblastoma cells treated with indicated compounds for 2 days (c, furamidine; d, pentamidine; e,
hexamidine; f, decamidine; g, TC-E5003), as determined by using Alamar blue assay. Data are mean ± SD (n ≥ 3) relative to DMSO control (100%).
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receptor interaction, and MAPK signaling pathways
were the most differentially expressed (Fig. 5e), sug-
gesting that decamidine treatment may partially reca-
pitulate effects of PRMT1-specific genetic ablation, as
well as trigger other downstream effects that are
PRMT1-independent (Fig. 3a, b).
To further investigate whether the anti-proliferative
effect of diamidine compounds is due to PRMT1 inhibi-
tion, we examined the sensitivity of cells to decamidine
under PRMT1 knockdown conditions. If decamidine
inhibits cell growth by solely targeting PRMT1, knock-
down of PRMT1 would increase the sensitivity of cells to
decamidine. Intriguingly, we found that PRMT1 silencing
dampened the cytotoxicity of decamidine in SK-N-BE(2)
C-shPRMT1-D6 cells (Fig. 5f). A likely explanation is
substrate scavenging previously observed upon loss of
PRMT122. In Prmt1-null cells, there are major increases
in global sDMA marks that are mainly deposited by
PRMT522. In good agreement with previous studies, we
observed in multiple and diverse PRMT1-depleted human
neuroblastoma cell lines an increase of sDMA levels along
with the expected decrease of aDMA levels, with no
detectable change of PRMT5 protein level (Supplemen-
tary Figure S3A-E). This observation is consistent with the
notion that loss of PRMT1 activity impacts substrate
protein function by switching to a different methylation
type mediated by PRMT522,23. Indeed, recent studies have
demonstrated a redundancy between PRMT1 and PRMT5
pathways and synergistic anti-tumor effects of combined
inhibition of both PRMTs23–25. In the context of neuro-
blastoma, knockdown of only PRMT1 or PRMT5 leads to
cell apoptosis (Fig. 2 and ref. 4). In addition, decamidine
was shown to bind to PRMT1 and PRMT5 similarly15.
Taken together, it is tempting to speculate that the
increased level of sDMA in PRMT1-depleted cells would
require more decamidine for inhibition of PRMT5 activ-
ity. However, we cannot rule out the possibility that other
molecular substrates, in addition to PRMT5, the activity
of which is modulated upon PRMT1 silencing, might
induce a prosurvival effect and thus counterbalance the
loss of PRMT1.
Finally, we investigated whether ATF5 mediates the
anti-proliferative effect of diamidine compounds. We
generated stable SK-N-BE(2)C cell lines overexpressing
pOZ vector or pOZ-ATF5 and validated the expression of
ectopic ATF5 (Fig. 5g). We observed a significant resis-
tance of ATF5-overexprssing cells to decamidine com-
pared to the vector-expressing cells at all the
concentrations tested (Fig. 5h). Therefore, the expression
level of ATF5 is associated with sensitivity to diamidine
compounds and ATF5 functions as a downstream effec-
tor of PRMT1 signaling to promote cell survival. Col-
lectively, these results provide multiple lines of evidence
supporting the specificity of diamidine compounds
Fig. 5 Pharmacological inhibition of PRMT1 suppresses cell growth and induces cell apoptosis in human neuroblastoma cells. a Caspase-3/
7 activity assay of SK-N-BE(2)C cells treated with indicated concentrations of decamidine for 24 h. Data are mean ± SD (n= 3) relative to DMSO
control. b Western blot of cells in (a). c Caspase-3/7 activity assay of Kelly cells treated with indicated concentrations of decamidine for 24 h. Data are
mean ± SD (n= 3) relative to DMSO control. d Western blot of cells in (c). e Gene ontology analysis of differentially expressed genes in SK-N-BE(2)C
cells following 24 h of treatment with 4-μM decamidine. f PRMT1 knockdown altered the sensitivity of SK-N-BE(2)C cells to decamidine. SK-N-BE(2)C
shPRMT1-D6 cells were treated with or without Dox for 3 days, followed by 24 h of treatment with indicated concentrations of decamidine. Cell
viability was determined by using Alamar blue assay. Data are mean ± SD (n= 3) relative to DMSO control (100%). gWestern blot of SK-N-BE(2)C cells
transduced with pOZ vector or pOZ-ATF5. h Cell viability of SK-N-BE(2)C cells stably expressing pOZ vector or pOZ-ATF5 treated with indicated
concentrations of decamidine for 24 h. Data are mean ± SD (n= 3) relative to DMSO control (100%). *P < 0.05; **P < 0.01.
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toward suppression of the PRMT1-ATF5 survival sig-
naling axis in neuroblastoma.
PRMT1 inhibitors impair the growth of established
neuroblastoma tumors
The Th-MYCN transgenic mice carry in the germline
human MYCN driven by a promoter of the rat tyrosine
hydroxylase gene (Th) which is expressed specifically in
neural crest lineage cells26. These animals spontaneously
develop neuroblastoma tumors that recapitulate many of
histological and pathological aspects of human neuro-
blastoma26. Four-week-old tumor-bearing Th-MYCN+/+
mice were treated with saline or furamidine (10 mg/kg)
daily for 10 days and the tumor volume was monitored by
ultrasound imaging (Fig. 6a, b). This dose of furamidine
did not cause a significant weight loss (Supplementary
Figure S4A-B). Treatment with furamidine significantly
suppressed tumor growth compared to the saline control
(Fig. 6c). Next, we extended these studies to two more
potent diamidine compounds, hexamidine and dec-
amidine. The doses we used (10 mg/kg of decamidine)
were well tolerated without causing a significant weight
loss (Supplementary Figure S4C-D). Consistent with the
higher in vitro potency of hexamidine and decamidine as
compared to furamidine, administration of hexamidine or
decamidine dramatically diminished tumor growth of
established neuroblastoma tumors (Fig. 6d, Supplemen-
tary Figure S4E-F). Importantly, assessment of tumor
lysates from mice treated with decamidine demonstrated
tumor cell apoptosis, as evidenced by elevated amounts of
cleaved PARP (Fig. 6e). Furthermore, we employed an
independent preclinical xenograft model of SK-N-BE(2)C
cells and decamidine treatment resulted in decreased
tumor growth (Supplementary Figure S4G).
Fig. 6 Diamidine compounds impair neuroblastoma tumor growth in vivo. a Schematic representation of progression of spontaneously
developing neuroblastoma tumor in homozygous Th-MYCN mice. The numbers shown are postnatal days. The drug treatment started from P28 for
10 days. b Representative ultrasound images of mice treated with saline or furamidine at P28 (start) and P38 (end). Tumors are indicated by asterisks.
c Tumor volume of mice treated with saline (n= 6) or furamidine (n= 9) at start and end points as determined by ultrasound imaging. d Tumor
volume of mice treated with DMSO (n= 7) or decamidine (n= 9) at start and end points as determined by ultrasound imaging. e Western blot of
tumor lysates from (d) at the end point. f The drug treatment started from P14 for 4 weeks and the tumor growth was assessed weekly by ultrasound
imaging. g Tumor volume of mice treated with saline (n= 11) or furamidine (n= 8). h A Kaplan–Meier plot for survival of mice in (g) treated with
saline or furamidine considering time to tumor burden (500 cubic mm by ultrasound imaging). Log-rank test was used to calculate statistical
significance between saline- and furamidine-treated tumors.
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Taken together, these results suggest that PRMT1 inhi-
bition with diamidine compounds may be an effective
therapeutic strategy for neuroblastoma.
Perinatal inhibition of PRMT1 activity suppresses
neuroblastoma tumor initiation and progression
Finally, we examined whether suppression of PRMT1
activity could block neuroblastoma tumor initiation. We
initially treated seven-day old Th-MYCN+/+ mice with
furamidine at 10 mg/kg for 4 cycles of 5 days on/2 days off
and observed improved animal survival, as well as a severe
loss of body weight (data not shown). We then adminis-
tered furamidine at 10 mg/kg from 2 weeks of age for 4
cycles (Fig. 6f). Mice treated with this regimen did not
show a significant weight loss and no other obvious
toxicity was observed (Supplementary Figure S4H-I).
Treatment with furamidine before tumor initiation sig-
nificantly inhibited subsequent tumor growth, reduced
tumor volume at the end of treatment by ~50% (Fig. 6g),
and extended animal survival (Fig. 6h). Together, these
data confirm a critical role of PRMT1 activity for the
initiation and progression of neuroblastoma tumor in a
well-established preclinical mouse model and suggest that
inhibition of PRMT1 activity may represent a promising
strategy for neuroblastoma.
Discussion
Here we present evidence supporting an essential
function of PRMT1-mediated survival pathway in neu-
roblastoma. Given multiple roles of arginine methylation,
the functional complexity of PRMTs is mainly reflected by
a large number of histone and non-histone substrates
involved in diverse cellular processes. Indeed, our prior
studies identified arginine methylation of MYCN and
subsequent enhancement of MYCN stability by PRMT1
and PRMT5 in neuroblastoma3,4. Our current results
reveal a new role for PRMT1 to promote cell survival
through modulating H4R3me2a mark at the prosurvival
gene ATF5. Notably, neuroblastoma cells are sensitive to
PRMT1 inhibition irrespective of MYCN amplification,
suggesting that additional biomarkers of response to
suppression of PRMT1 activity are likely to be relevant.
We propose that PRMT1 may exert its functions through
multiple and non-mutually exclusive mechanisms to sti-
mulate neuroblastoma cell growth.
In neuroblastomas with MYCN amplification or high
MYCN levels without MYCN amplification, the positive
regulatory loop of the MYCN-PRMT1 axis may promote
a MYCN-driven oncogenic program3,6 whereas PRMT1-
mediated activation of ATF5 may lead to enhanced sur-
vival. We speculate that there may be cross regulatory
mechanisms between PRMT1-MYCN and PRMT1-ATF5
axes. This idea is supported by initial findings by Yama-
shiro’s group demonstrating ATF5 as a potential synthetic
lethal gene to MYCN-amplified neuroblastoma10,
although the mechanistic link between MYCN and ATF5
remains to be characterized. On the other hand, a similar
role of the PRMT1-ATF5 axis may apply to neuro-
blastomas with low MYCN levels. This notion is sup-
ported by our current work revealing downregulation of
ATF5 in PRMT1 knockdown cells regardless of MYCN
amplification status, and similar sensitivity in MYCN-
non-amplified neuroblastoma cells to PRMT1 inhibition
as that in MYCN-amplified cells, as well as by initial
studies of ATF5 in neuroblastoma11. Yamashiro’s group
found that suppression of ATF5 activity with an inhibitory
peptide led to a concentration-dependent decrease of cell
viability and increase of cell apoptosis in a panel of human
neuroblastoma cell lines regardless of MYCN amplifica-
tion11. Therefore, it is tempting to speculate that ATF5
may act as a general downstream effector of PRMT1-
mediated survival signaling in neuroblastoma. Active
investigations are now underway to test this hypothesis.
However, we cannot rule out the possibility that MYCN
may directly or indirectly regulate ATF5 in MYCN-
amplified cells. Furthermore, it is noteworthy that PRMT1
has been recently shown to modulate cellular senescence
and migration activity in a non-MYCN-amplified neuro-
blastoma SK-N-SH cell line27. Seminal studies have
demonstrated phenotypically divergent subclones that are
derived from SK-N-SH cell line and that these subclones
may interconvert28,29. Our results indicate a prosurvival
role of PRMT1 in a panel of human neuroblastoma cell
lines comprising of major phenotypically divergent cell
types. Further dissection of downstream signaling events
of PRMT1 is needed to fully reveal the multifaceted
complexity of this epigenetic factor as a regulator of
neuroblastoma.
Until recently, small molecule inhibition of PRMT1 has
not yet been fully explored in cancer therapy largely due
to issues pertaining to specificity, selectivity, potency, and
cellular permeability1,14. In our current study, multiple
lines of evidence have verified these properties of diami-
dine compounds. However, as with many targeted com-
pounds, targeting epigenetic modifiers as a monotherapy
often results in only modest therapeutic effects. We have
noted from our in vivo studies that PRMT1 inhibition
alone may not be sufficient to completely ablate tumor
formation and progression. Interestingly, recent studies
have provided a rational combinatorial inhibition strategy
of type I PRMTs and PRMT5 for synergistic killing of
cancer cells23–25. The dual inhibition of PRMT1 and
PRMT5 has not yet been evaluated in neuroblastoma. We
predict that simultaneous targeting of PRMT1 and
PRMT5 may prove more efficacious based on the fol-
lowing reasons. Frist, PRMT1 and PRMT5 may share
common substrates that are similarly regulated by both
aDMA and sDMA marks. Our prior identification of
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MYCN as a shared substrate for PRMT1 and
PRMT5 suggests that arginine methylation of MYCN
plays a critical role for the stabilization of MYCN and
subsequent MYCN-driven oncogenic program3,4. The
mechanistic interplay between aDMA and sDMA of
MYCN is currently unclear, but it appears that a certain
threshold of arginine methylation regardless of whether it
is aDMA or sDMA is required for cell survival, as
demonstrated by induction of cell apoptosis in cells
depleted of either PRMT1 or PRMT5 through RNA
interference3,4. This idea is supported by a recent report
showing that MYC is both asymmetrically and symme-
trically dimethylated by PRMT1 and PRMT5, respectively,
with different functional properties in glioblastoma30.
Second, the high potency of decamidine we observed in
our current study may be due to combined PRMT1 and
PRMT5 inhibition. Compared with all the other diami-
dine compounds, decamidine possesses the most potent
inhibitory effect toward PRMT1, but slightly decreased
selectivity against PRMT515. It is likely that simultaneous
inhibition of PRMT1 and PRMT5 by decamidine on
common or distinct substrates, such as MYCN or MYC
brings the overall arginine methylation levels below the
threshold required for cell growth and survival. Intrigu-
ingly, we observed an increased resistance to decamidine
in PRMT1 knockdown cells. This is likely due to substrate
scavenging by other PRMTs upon loss of PRMT122 and
the compensatory accumulation of sDMA and MMA
marks may render PRMT1-depleted cells more resistant
to decamidine. It is important to note that the synergy
between PRMT1 and PRMT5 results from a complicated
cross-talk between PRMT1 and PRMT5 on many under-
characterized substrates and through diverse downstream
signaling events23–25. Indeed, we found that the currently
available PRMT5 inhibitors, such as EPZ015666 were not
able to recapitulate the sensitivity of human neuro-
blastoma cells in response to depletion of PRMT1 or
PRMT5 (data not shown). This discrepancy between
genetic depletion and pharmacological inhibition of
PRMTs has been previously described in a number of
cancers and warrants further investigation23–25. Impor-
tantly, our studies indicate that regulation of MAPK
kinase activity, separate from apoptosis pathway, is among
the most significantly regulated effects of PRMT1 deple-
tion on neuroblastoma cells. This is critically important,
as neuroblastomas at relapse harbor an increased spec-
trum of mutations or structural alterations predicted to
activate the RAS-MAPK pathway31,32. A substantial array
of therapeutic approaches to target the RAS-MAPK sig-
naling is currently on the horizon for cancer therapy. A
better understanding of how PRMTs modulate specific
oncogenic pathways will provide insights into novel
combinational therapies in high-risk and relapsed neu-
roblastomas, and possibly other cancers.
In summary, we have uncovered an essential survival
pathway mediated by the PRMT1-ATF5 axis in neuro-
blastoma. PRMT1 promotes cell survival through epige-
netic activation of the prosurvival factor ATF5, thus
providing a new mechanistic link between overexpression
of PRMT1 and compromised apoptotic pathway, a
malignant phenotype characteristic of a large number of
cancers, including neuroblastoma. We also assessed the
therapeutic relevance of PRMT1 inhibition with diami-
dine compounds using multiple relevant in vitro and
in vivo model systems. Collectively, our results reveal that
PRMT1-depdenent survival pathway provides potential
druggable targets for neuroblastoma.
Materials and methods
Reagents
Furamidine, pentamidine, hexamidine, and TC-E5003
were purchased from Tocris. Decamidine and SKLB639
were described previously15,17. Antibodies used in this
study include PRMT13, PRMT5 (Millipore), aDMA (Cell
Signaling), sDMA (Millipore), MYCN3, TH (Millipore),
PHOX2B (Abcam), PARP (Cell Signaling), ATF5
(Abcam), Flag (Thermo Fisher Scientific), and β-actin3.
Cell culture
Human neuroblastoma cell lines KELLY, SK-N-BE(2)-
C, SH-SY5Y, and SK-N-AS were purchased from Sigma
and ATCC, respectively. SH-EP1 cells were generously
provided by Dr. Karim Malik. All cell lines have been
authenticated using STR profiling (Fragment Analysis
Facility, Johns Hopkins University) and tested for myco-
plasma using PCR Mycoplasma Test Kit I/C. Cell viability
and cell proliferation were performed by using Alamar
blue and trypan blue staining as previously described3.
Caspase-3/7 activities were detected using a Caspase-Glo
3/7 Assay according to the manufacturer’s instruction.
Alamar blue assay was performed in parallel to control for
the differences in cell number.
Plasmids, transfection, and viral infection
The inducible knockdown constructs were generated by
cloning shPRMT1 sequences3 into pTRIPZ and pTER
vectors33. ATF5 expression construct was made by clon-
ing ATF5 cDNA34 to pOZ-FH-N vector. Transfection was
carried out by using Nucleofector3. siRNA transfection
was performed by using ON-TARGETplus siRNA pool
(Dharmacon) and Lipofectamine® RNAiMAX (Thermo
Fisher). The infectious viruses were produced by calcium
phosphate transfection as previously described8. Cells
were selected with 1 μg/mL puromycin 24 h post-
transfection or post-infection. PRMT1 rescue construct
was described previously8. Rescued cells were sorted by
using anti-interleukin-2 receptor-conjugated Dynabeads
as previously described8.
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Animals and primary sphere cell culture
All animal experiments were conducted under the
approval of the University of Rochester Institutional
Animal Care and Use Committee. Th-MYCN mice were
obtained from NCI Mouse Repository and maintained in
a 129X1/SvJ background. Genotyping was carried out as
previously described35. Tumors were visualized by
abdominal ultrasound using a Vevo 3100 Imaging System
and MX550D transducer. 3D volume measurements were
carried out using Amira 6.1 software. Ultrasound imaging
analysis was made by individuals blinded to the genotype,
appearance, and treatment history of the mice. Neuro-
blastoma spheres were isolated from tumors of Th-MYCN
homozygous mice and sphere growth, sphere forming and
syngeneic tumor transplantation assays were performed
as described previously7.
Based on the power analysis, a group size of n= 10 will
provide 90% power to detect a difference of 22% between
two groups of mice with a 5% significance level (two-sided
t test).
Immunoblotting and immunohistochemistry
Immunoblotting and immunohistochemical studies
were performed essentially as previously described3,36.
RNA analysis
Total RNA was extracted using the RNeasy Plus mini kit
and RT-qPCR was performed as previously described3.
RNA-seq and transcriptome analyses were completed by
the University of Rochester Genomics Research Center.
Gene ontology (GO) enrichment analysis was carried out
by using cluster Profiler (v3.8.1) and visualized by ggplot2
(v2.2.1) and GO plot (v1.0.2)37,38. A Benjamini–Hochberg
adjust P value <0.05 and fold change cutoff as log2 ratio ≥1
were used for detection of differentially expressed genes.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as described previously8
using antibodies specific for PRMT1 or H4R3me2a (Active
Motif). The primers used for ChIP-qPCR are ATF5
promoter (Forward: TGGGAAGGAAAGGCTCGGAT;




Statistics were determined using Prism 7 software. Data
were presented as mean ± SD. P-values of <0.05 (*) and
<0.01 (**) were considered statistically significant.
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